Current perspectives on HER2 testing: A review of National Testing Guidelines

Modern Pathology

Volumn 16, Issue 2, 2003, Pages 173-182

  Bilous, Michael ^a   Dowsett, Mitch ^b   Hanna, Wedad ^c,k   Isola, Jorma ^d   Lebeau, Annette ^e   Moreno, Aberlardo ^f   Penault Llorca, Frédérique ^g   Rüschoff, Josef ^h   Tomasic, Gorana ⁱ   Van de Vijver, Marc ^j  

^a WESTMEAD HOSPITAL   (Australia)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e UNIVERSITY OF MUNICH   (Germany)

^f Ciutat Santatia de Bellvitge   (Spain)

^g CENTRE JEAN PERRIN   (France)

^h Institut für Pathologie   (Germany)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j NETHERLANDS CANCER INSTITUTE   (Netherlands)

^k SUNNYBROOK RESEARCH INSTITUTE   (Canada)

more..

Author keywords

Breast cancer; Fluorescence in situ hybridization; HER2; Immunohistochemistry; Testing guidelines

Indexed keywords

NEU DIFFERENTIATION FACTOR; TRASTUZUMAB;

ALGORITHM; ARTICLE; BREAST CANCER; CHROMOGENIC IN SITU HYBRIDIZATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; METHODOLOGY; MOLECULAR BIOLOGY; ONCOGENE NEU; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; SOUTHERN BLOTTING; TISSUE FIXATION; TISSUE PREPARATION; TISSUE PRESERVATION; TISSUE SECTION; VALIDATION PROCESS;

ALGORITHMS; BREAST NEOPLASMS; GENETIC SCREENING; HEALTH PLANNING GUIDELINES; HISTOCYTOLOGICAL PREPARATION TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; QUALITY CONTROL; RECEPTOR, ERBB-2;

EID: 0037325177     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000052102.90815.82     Document Type: Article

References (66)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Slamon D, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
3. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-28.
4. Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000;36:170-6.
5. Piccart M, Lohrisch C, Di Leo A, Larismont D. The predictive value of HER2 in breast cancer. Oncology 2001;61(Suppl 2):73-82.
6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
8. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
9. Mass RD, Press M, Anderson S, Murphy M, Slamon D. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) [abstract]. Proc Am Soc Clin Oncol 2001;20:22a.
10. Vogel CL, Cobleigh D, Tripathy D, Mass R, Murphy M, Stewart SJ. Superior outcomes with Herceptin (trastuzumab) (H) in fluororescence in situ hybridization (FISH)-selected patients [abstract]. Proc Am Soc Clin Oncol 2001;20:22a.
11. Smith IE. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs 2001;12(Suppl 4):S3-10.
12. Bilous M. HER2 testing recommendations in Australia. Pathology 2001;33:425-7.
13. Hanna W, O'Malley FO. Updated recommendations from the HER2/neu consensus meeting - Toronto, Ontario, 7 September, 2001. Curr Oncol 2002;9:S18-20.
14. Penault-Llorca F, Balaton A, Sabourin JC, Le Doussal V. Immunohistochemical evaluation of HER2 status in infiltrating breast cancers: development of technical protocol and reading of results - recommendations. Ann Pathol 2002;22:150-7.
15. Schaller G. Metastasiertes mammakarzinom: welche patientinnen profitieren von einer antikörper-therapie? Dtsch Arzteblatt 2001;98:A3014-5.
16. Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, et al. Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological Committee for Optimal use of Trastuzumab). Breast Cancer 2001;8:316-20.
17. Ellis IO, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000;53:890-2.
18. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
19. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
20. Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S, et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001;12:615-20.
21. Gancberg M, Di Leo A, Rouas G, Pedrocchi M, Paesmans M, Verhast A. Comparison of Topo-isomerase IIα (topoIIα) and HER-2 status between primary (P) breast cancer (BC) and corresponding metastatic (M) sites [abstract]. Proc Am Assoc Cancer Res 2001;42:8.
22. Larsimont D, Di Leo A, Rouas G, Pedrocchi M, Paesmans M, Verhast A, et al. Primary versus metastatic breast cancer. A comparison of HER-2 and Topo-Isomerase IIα status [abstract]. Proc Am Soc Clin Oncol 2001;20:426a.
23. Lower EE, Yassin IR, Blau IR, Heffelfingers S. HER-2/neu expression in primary breast cancer correlates with metastatic disease expression [abstract]. Proc Am Soc Clin Oncol 2001;20:425a.
24. Simon R, Nocito A, Hubscher T, Bucher C, Torhurst J, Schraml P, et al. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-6.
25. Tanner M, Järvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer Res 2001;61:5345-8.
26. De Laurentiis M, Caputo F, Massarelli E, Forestieri V, Vernaglia A, Carlomagno C, et al. HER2 expression and anthracycline effect: results from the Naples GUN3 randomised trial [abstract]. Proc Am Soc Clin Oncol 2001;20:34a.
27. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B- 15. J Natl Cancer Inst 2000;92:1991-8.
28. Ravdin PM, Green S, Albain V, Boucher V, Ingle J, Pritchard K, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF with tamoxifen (T) alone [abstract]. Proc Am Soc Clin Oncol 1998;17:97a.
29. Thor AD, Berry DA, Budmann DR, Muss HB, Kute T, Henderson IC, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-60.
30. Bianco AR, De Laurentiis M, Carlomagno C, Gallo C, Panico L, De Placido S. HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for elderly breast cancer (EBC): complete data at 20 yr of the Naples GUN randomized trial [abstract]. Proc Am Soc Clin Oncol 2000;19:75a.
31. Colomer R, Llombart A, Ramos M, Mayordomo JI, Fernandez R, Tusquets I, et al. Serum HER-2 ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: preliminary results of a prospective study [abstract]. Breast Cancer Res Treat 2001;69:242.
32. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994;14:1441-50.
33. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-72.
34. Still O, Borg A, Ferno M, Kallstrom AC, Malmstrom P, Nordenskjold B. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 2000;11:1545-50.
35. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16.
36. McManus DT, Patterson AH, Maxwell P, Humphreys MW, Anderson NH. Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates. Mol Pathol 1999;52:75-7.
37. Mezzelani A, Alasio L, Bartoli C, Bonora MG, Pierotti MA, Rilke F. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 1999;80:519-25.
38. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status in breast cancer using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7.
39. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 1994;173:65-75.
40. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di Leo A, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 2000;113:675-82.
41. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-63.
42. O'Malley FP, Parkes R, Latta E, Tjan S, Zadro T, Mueller R, et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 2001;115:504-11.
43. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
44. Thomson TA, Hayes MM, Spinelli JJ, Hiland E, Sawrenko C, Phillip D, et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001;14:1079-86.
45. Farabegoli F, Ceccarelli C, Santini D, Baldini N, Taffurelli M, Marrano D, et al. c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples. Int J Cancer 1999;84:273-7.
46. Shi SR, Imam SA, Young L, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry under the influence of pH using monoclonal antibodies. J Histochem Cytochem 1995;43:193-201.
47. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001;7:1669-75.
48. Di Leo A, Dowsett M, Horten B, Penault-Llorca F. Current status of HER2 testing. Oncology 2002;63(Suppl 1):25-32.
49. Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 1999;17:434.
50. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-21.
51. Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002;117:81-9.
52. Hoang MP, Sahin AA, Ordòñez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:852-9.
53. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974-82.
54. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
55. Onody P, Bertrand F, Muzeau F, Bieche I, Lidereau R. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer. Arch Pathol Lab Med 2001;125:746-50.
56. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000;13:866-73.
57. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374-81.
58. Bloom K, de la Torre-Bueno J, Press M, Gown A, Bauer K, Harrington D. Comparison of HER-2/neu analysis using FISH and IHC when HercepTest is scored using conventional microscopy and image analysis [abstract]. Breast Cancer Res Treat 2000;64:99.
59. Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 1994;47:816-22.
60. Torre-Bueno J, Harrington DS, Bauer KD. Use of image analysis to improve accuracy of reading HER2Neu status by IHC [abstract]. Proc Am Assoc Cancer Res 2001;42:118.
61. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 2001;14:677-85.
62. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta Rev Cancer 1994;1198:165-84.
63. Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
64. Bilous M. Predicting HER2 status of breast cancer from basic pathology features: HER2 status of 1500 breast cancers determined by immunohistochemistry and fluorescence in situ hybridisation with pathology correlation [abstract]. Eur J Cancer 2002;38:S52.
65. Persons DL, Bui MM, Lowery MC, Mark HF, Yung JF, Birkmeier JM, et al. Fluorescence in situ hybridization (FISH) for the detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci 2000;30:41-8.
66. Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology 2002;63(Suppl 1):57-63.